ClinicalTrials.gg
CompletedNCT07852598Updated Oct 1, 2026

A Metagenomic Next-generation Sequencing (mNGS)-Guided Sequential Culture Strategy for Postoperative Cruciate Ligament Reconstruction Infection (CLRI): a Retrospective Cohort Study

An observational study in Cruciate Ligament Reconstruction Infection, Septic Arthritis and Surgical Wound Infection, sponsored by First Affiliated Hospital of Fujian Medical University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by First Affiliated Hospital of Fujian Medical University · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
80
Sex
All
01

Study summary

This retrospective cohort study evaluates a sequential diagnostic strategy for patients with postoperative cruciate ligament reconstruction infection (CLRI). Diagnosing these infections is often difficult because conventional laboratory cultures can easily miss fastidious or slow-growing microorganisms. This study investigates whether using a rapid DNA-based test called metagenomic next-generation sequencing (mNGS) to guide and customize subsequent laboratory culture conditions can improve the detection rate of viable, live pathogens. The study includes 50 patients with CLRI and 30 patients with aseptic failure (non-infectious complications). The ultimate goal is to determine if this mNGS-guided modified culture strategy can help doctors identify the exact infection-causing germs more accurately, thereby allowing them to provide targeted, individualized antibiotic and surgical treatments.

Read the detailed description

English Version :

This is a retrospective, single-center cohort study evaluating patients evaluated for suspected postoperative cruciate ligament reconstruction infection (CLRI) between January 2015 and January 2026. The study enrolled 50 patients who were clinically diagnosed with CLRI and 30 comparator patients who underwent revision surgery for aseptic failure (AF). Study Protocol:

Pre-therapy synovial fluid was aspirated under sterile conditions and divided into at least three aliquots. Conventional Culture: The first aliquot was processed immediately using routine aerobic and anaerobic microbiological culture methods (incubated for up to 7-14 days). mNGS Testing: The second aliquot was transported immediately for metagenomic next-generation sequencing (mNGS) testing to quickly identify potential microbial nucleic acids. mNGS-Guided Modified Culture: The third aliquot was preserved at -80°C. Once the mNGS result became available (within 48 hours), a clinical microbiologist reviewed the detected microorganisms and prescribed individualized modifications to the subsequent culture protocol for the preserved aliquot. These modifications were tailored to the suspected pathogen's biological characteristics and included the use of specialized culture media (e.g., Sabouraud dextrose agar, Mycobacteria Growth Indicator Tube systems), prolonged incubation, strictly anaerobic conditions, and supplementary identification procedures. Objectives and Assessments:

The primary objective is to compare the diagnostic yield (positive detection rates of viable pathogens) among pre-therapy conventional culture, pre-therapy mNGS, and the sequential mNGS-guided modified culture strategy. The study also evaluates how this enhanced, actionable microbiological information informs individualized clinical management. Specifically, it assesses treatment decision-making algorithms-integrating pathogen characteristics, infection duration, and graft/fixation mechanical stability-to determine the feasibility of non-operative antimicrobial management or graft-preserving surgical options such as debridement, antibiotics, and implant retention (DAIR).

02

Conditions studied

  • Cruciate Ligament Reconstruction Infection
  • Septic Arthritis
  • Surgical Wound Infection
  • Joint Infection

Keywords

  • metagenomic next-generation sequencing
  • mNGS
  • synovial fluid culture
  • pathogen detection
  • antimicrobial management
03

In context

Arthritis, Infectious

51 studies on the registry are indexed under Arthritis, Infectious; 12 are open to participants now.

This study's enrollment of 80 is below the median of 100 across 30 observational studies indexed under Arthritis, Infectious.

Browse Arthritis, Infectious studies →

Lead sponsor

First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients who were evaluated and treated for suspected postoperative cruciate ligament reconstruction infection (CLRI) or who underwent revision surgery for aseptic failure (AF) at a single tertiary referral center (The First Affiliated Hospital of Fujian Medical University) between January 2015 and January 2026. This includes both patients treated primarily at this center and those referred from other hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinically diagnosed cruciate ligament reconstruction infection (CLRI) or patients who underwent revision surgery for aseptic failure (AF).

Preoperative joint aspiration performed at our institution.

Adequate preoperative samples available for concurrent microbial culture and metagenomic next-generation sequencing (mNGS) testing.

Complete clinical and laboratory data.

Exclusion criteria

Exclusion Criteria:

Specimen contamination (e.g., specimens clearly contaminated during collection or processing, or microorganisms isolated from only a single culture that did not align with the clinical judgement of the expert team).

Concomitant systemic inflammatory disease or that could interfere with laboratory test results.

Long-term use of drugs or .

Missing key clinical data.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • CLRI Group

    Patients clinically diagnosed with postoperative cruciate ligament reconstruction infection (CLRI) who underwent preoperative joint aspiration.

    Diagnostic Test: Metagenomic next-generation sequencing (mNGS) · Diagnostic Test: mNGS-guided modified culture · Diagnostic Test: Conventional microbiological culture

  • Aseptic Failure (AF) Group

    Comparator patients undergoing revision surgery for aseptic failure (AF), defined by the absence of clinical, laboratory, imaging, and microbiological evidence of infection.

    Diagnostic Test: Metagenomic next-generation sequencing (mNGS) · Diagnostic Test: mNGS-guided modified culture · Diagnostic Test: Conventional microbiological culture

Interventions

  • Diagnostic testMetagenomic next-generation sequencing (mNGS)

    Pre-therapy synovial fluid was analyzed by mNGS to rapidly detect microbial nucleic acids and identify potential pathogens.

  • Diagnostic testmNGS-guided modified culture

    A subsequent synovial fluid culture protocol customized based on pre-therapy mNGS results, utilizing specialized media, prolonged incubation, or specific atmospheric conditions to improve viable pathogen recovery.

  • Diagnostic testConventional microbiological culture

    Routine aerobic and anaerobic microbiological culture methods used as the standard baseline test.

06

What researchers measure

Primary outcomes

  1. Pathogen Detection Rate

    The percentage of patients in whom potential or viable microorganisms were successfully detected from pre-therapy synovial fluid. This measure compares the diagnostic yield among pre-therapy conventional culture, pre-therapy metagenomic next-generation sequencing (mNGS), and the mNGS-guided modified culture strategy.

    Time frame: Up to 14 days after synovial fluid aspiration (based on the maximum culture incubation period).

Secondary outcomes

  1. Rate of Clinical Infection Control (Treatment Success)

    The percentage of patients achieving successful infection management and clinical infection control, defined according to the consensus criteria of the Musculoskeletal Infection Society (MSIS). This evaluates the clinical outcome after individualized antimicrobial and surgical management.

    Time frame: At the last follow-up (minimum 6 months after discharge).

07

Study locations

1 site
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
08

References and documents

Individual participant data

Plan to share: Yes — The datasets analysed during the current study are not publicly available because they contain information that could compromise patient privacy, but are available from the corresponding author on reasonable request.

Supporting information: Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jan 2026, 132 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
Jan 1, 2015
Primary completionActual
Jan 5, 2026
CompletionActual
Feb 5, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852598
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Xinyu Fang (Chief physician, First Affiliated Hospital of Fujian Medical University) — Principal investigator
First posted
Oct 1, 2026
Start date
Jan 1, 2015
Primary completion
Jan 5, 2026
Completion
Feb 5, 2026
Last update
Oct 1, 2026

Study contacts

Liu Zhang
study director · First Affiliated Hospital of Fujian Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion